2025年05月31日 星期六 首页   |   期刊介绍   |   编 委 会   |   投稿指南   |   期刊订阅   |   广告合作   |   联系我们   |   ENGLISH
哈尔滨医药  2024, Vol. 44 Issue (2): 24-27    DOI: 10.3969/j.issn.1001-8131.2024.02.008
  论著 本期目录 | 过刊浏览 | 高级检索 |
冠心病伴T2DM患者血清Lp(a)水平变化与冠脉病变程度的关系探讨
王东东, 陈招进
联勤保障部队第九八八医院检验科,河南 郑州 450000
The Relationship between Serum Lp(a)Level and The Degree of Coronary Artery Disease in Patients with Coronary Heart Disease and T2DM
Wang Dongdong, Chen Zhaojin
Department of Clinical Laboratory,988 Hospital of Joint Logistic Support Force,Zhengzhou,Henan 450000
全文: PDF (611 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 探究冠心病(CHD)伴2型糖尿病(T2DM)患者血脂蛋白a[Lp(a)]水平与冠脉病变程度的关系。方法 选取T2DM的患者123例,其中110例经冠状动脉造影(CAG)证实合并CHD,将其按冠脉狭窄程度分为中度狭窄组(30例)和重度狭窄组(80例),按冠脉病变范围分为单支病变组(25例)、双支病变组(55例)和多支病变组(30例)。另选取同期在本院就诊的正常冠脉志愿者30例作为对照组,分别测量各组血脂、载脂蛋白A1(ApoA1)、载脂蛋白B(ApoB)以及Lp(a)水平。结果 与对照组相比,CHD伴T2DM组患者的TG、Lp(a)水平均更高,但其HDL-C水平较对照组更低(P<0.05)。对照组、中度狭窄组、重度狭窄组的Lp(a)水平分别为(115.20±54.09)mg/L、(158.90±65.12)mg/L、(183.20±55.45)mg/L,重度狭窄组>中度狭窄组>对照组。对照组、单支组、双支组以及多支病变组的Lp(a)水平分别为(115.20±54.09)mg/L、(128.90±68.23)mg/L、(186.47±91.23)mg/L、(261.90±109.47)mg/L,多支病变组>双支病变组>单支病变组(P<0.05),但单支病变组与对照组的Lp(a)水平比较差异无统计学意义(P>0.05)。当Lp(a)>147.82mg/L时,其诊断CHD伴T2DM的AUC为0.821(0.747~0.881),灵敏度、特异度分别为77.27%和83.33%(P<0.05)。结论 CHD伴T2DM患者Lp(a)水平随冠脉狭窄程度加重以及冠脉支数的增加而升高,临床可将Lp(a)作为冠脉病变程度情况判定的一个重要辅助指标以辅助临床的诊疗。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
王东东
陈招进
关键词 冠心病2型糖尿病血脂蛋白a冠状动脉疾病血脂代谢    
AbstractObjective To investigate the relationship between the level of lipid protein a[Lp(a)] and the degree of coronary artery disease in patients with coronary heart disease(CHD)and type 2 diabetes mellitus(T2DM). Method A total of 123 patients diagnosed with T2DM were selected,110 of whom were confirmed by coronary angiography(CAG)with CHD,and divided into moderate stenosis group(30 cases)and severe stenosis group(80 cases)according to the degree of coronary artery stenosis.According to the range of coronary artery lesions,the patients were divided into single-vessel lesion group(25 cases),double-vessel lesion group(55 cases)and multi-vessel lesion group(30 cases).In addition,30 volunteers with normal coronary artery artery treated in our hospital during the same period were selected as the control group,and the levels of blood lipid,apolipoprotein A1(ApoA1),Apolipoprotein B(ApoB)and Lp(a)in each group were measured. Results Compared with the control group,TG and Lp(a)levels were higher in the CHD with T2DM group,but HDL-C level was lower than that in the control group(P<0.05).The Lp(a)levels in control group,moderate stenosis group and severe stenosis group were(115.20±54.09)mg/L,(158.90±65.12)mg/L and(183.20±55.45)mg/L,with severe stenosis group>moderate stenosis group>control group.Lp(a)levels in control group,single arm group,double arm group and multi-arm lesion group were(115.20±54.09)mg/L,(128.90±68.23)mg/L,(186.47±91.23)mg/L,(261.90±109.47)mg/L.Multibranch lesion group>double-branch lesion group>single-branch lesion group(P<0.05),but there was no significant difference in Lp(a)level between single-branch lesion group and control group(P>0.05).When Lp(a)>147.82mg/L,the AUC of CHD with T2DM was 0.821(0.747-0.881),and the sensitivity and specificity were 77.27% and 83.33%,respectively(P<0.05). Conclusion The level of Lp(a)in CHD patients with T2DM increases with the severity of coronary artery stenosis and the increase of coronary artery number.Lp(a)can be used as an important auxiliary index to determine the severity of coronary artery lesions to assist clinical diagnosis and treatment.
Key wordscoronary heart disease    Type 2 diabetes mellitus    Lipoprotein a    Coronary artery disease    Lipid metabolism
收稿日期: 2023-04-11     
PACS:  R541.4  
通讯作者: 陈招进   
引用本文:   
王东东, 陈招进. 冠心病伴T2DM患者血清Lp(a)水平变化与冠脉病变程度的关系探讨[J]. 哈尔滨医药, 2024, 44(2): 24-27.
Wang Dongdong, Chen Zhaojin. The Relationship between Serum Lp(a)Level and The Degree of Coronary Artery Disease in Patients with Coronary Heart Disease and T2DM. journal1, 2024, 44(2): 24-27.
链接本文:  
http://www.hrbyybjb.org.cn/CN/10.3969/j.issn.1001-8131.2024.02.008     或     http://www.hrbyybjb.org.cn/CN/Y2024/V44/I2/24
版权所有 © 《哈尔滨医药》编辑部  备案号: 黑ICP备19005758号-1
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:support@magtech.com.cn